The effect of the human immunodeficiency virus-1 protein Tat was investigated on neurotransmitter release from human and rat cortical nerve endings. Tat failed to affect the release of several neurotransmitters, such as glutamate, GABA, norepinephrine, and others, but it evoked the release of 
Introduction
During human immunodeficiency virus (HIV-1) infection, ϳ50% of patients develop motor, cognitive, and behavioral impairments, the origins of which are poorly understood. Because neurons can rarely, if ever, be infected by the virus, it is hypothesized that indirect mechanisms are primarily involved in the neuronal deficits and in the neurotoxic events that often occur during acquired immunodeficiency syndrome (AIDS) infection (Kaul and Lipton, 1999; Valle et al., 2000; Bezzi et al., 2001; Kaul et al., 2001; Mollace et al., 2001) , although direct effects of HIV-1 proteins have been reported as well (see below).
The occurrence of neurotoxic events is sustained by postmortem histological observations made in cerebral tissue from HIV-1-positive patients, where loss of neurons has clearly been described (Masliah et al., 1992 Adle-Biassette et al., 1995; Glass et al., 1995; Petito and Roberts, 1995; Fox et al., 1997; Everall et al., 1999) . These dramatic effects may, however, not be necessary to explain the above-mentioned neuropsychiatric deficits; in fact, relatively subtle changes in central neurotransmission induced by HIV-1 itself or by viral proteins might be at the basis of various functional impairments.
In the last decade, evidence has been provided suggesting that HIV-1 proteins, in particular the coat protein gp120, could directly influence central neuronal functions, causing changes in neurotransmitter release or affecting receptor-mediated mechanisms (Müller et al., 1992; Savio and Levi, 1993; Ushijima et al., 1993; Pittaluga and Raiteri, 1994; Lannuzel et al., 1995; Nath et al., 1995; Pittaluga et al., 1996; Fontana et al., 1997; Pattarini et al., 1998; Kaul and Lipton, 1999; Xin et al., 1999; Gemignani et al., 2000; Bezzi et al., 2001; Kaul et al., 2001) .
Increasing attention has been focused on Tat, a nonstructural viral protein known to be produced and actively released by HIV-1-infected cells (Ensoli et al., 1993) . Tat has been detected in the brain of animals with viral encephalitis, and its encoding mRNA has been found in the CNS of HIV-1-infected patients exhibiting AIDS-dementia symptoms (Hudson et al., 2000; Valle et al., 2000) .
Tat can apparently induce both neurological impairments and neurotoxicity because it was shown both to excite and kill human and rodent cerebrocortical neurons (Nath et al., 1996; Kruman et al., 1998) by mechanisms involving neuronal Ca 2ϩ homeostasis (Haughey et al., 1999 (Haughey et al., , 2001 . The protein binds to and depolarizes neuronal membranes (Sabatier et al., 1991) , allowing increases in cytosolic Ca 2ϩ through receptor-operated channels and mobilization from IP 3 -sensitive internal stores (Nath et al., 1996; Haughey et al., 1999 Haughey et al., , 2001 .
We investigated whether Tat can affect brain neurotransmission by affecting transmitter release from fresh human and rat cortical nerve endings. We first explored the release of several transmitters present in brain cortical areas and potentially involved in neuronal functions that can be impaired during HIV-1 infection (McGaugh, 1989; Hasselmo and Bower, 1993; Collingridge and Bliss, 1995; Garg, 1999; Gruslin et al., 1999; Pascual Sedano et al., 1999 ). Most of the work then focused on ACh, the release of which appears to be selectively targeted by Tat.
Materials and Methods
Human brain tissue samples. Samples of human cerebral cortex were obtained from informed and consentient HIV-1-negative patients undergoing neurosurgery, each on a different day, to reach deeply seated tumors. The samples represented parts of frontal (n ϭ 9) and temporal (n ϭ 7) lobes obtained from 11 women and 5 men (age, 30 -70 years) . Immediately after removal, the tissue was placed in a physiological salt solution at 2-4°C, and crude synaptosomal fractions were prepared within 90 min. The experimental procedures were approved by the Ethical Committee of the University of Genoa.
Rat brain tissue samples. Adult male rats (Sprague Dawley; 200 -250 gm) were housed at constant temperature (22 Ϯ 1°C) and relative humidity (50%) under a regular light/dark schedule (light, 7:00 A.M. to 7:00 P.M.). Food and water were freely available. The animals were killed by decapitation, and the tissue was rapidly removed. The experimental procedures were approved by the Department Ethical Committee, in accordance with European legislation (European Communities Council directive of November 24, 1986; 86/609/EEC).
Preparation of synaptosomes. Crude synaptosomal fractions were prepared essentially according to Raiteri et al. (1984) . Briefly, the tissue was homogenized in 40 volumes of 0.32 M sucrose, buffered with phosphate to pH 7.4; the homogenate was first centrifuged (5 min at 1000 ϫ g), and the synaptosomal fraction was isolated from the supernatant by centrifugation (20 min at 12,000 ϫ g). In a set of experiments, the tissue was homogenized in buffered sucrose containing 1 mM BAPTA or 40 M heparin, to entrap these membrane-impermeant agents into subsequently isolated synaptosomes . Based on estimates made by entrapping [ 3 H]sucrose, the intrasynaptosomal concentration of the compounds are ϳ5% of the original concentration in the homogenization medium. The synaptosomal pellets were resuspended in a physiological medium having the following composition (in mM): 125 NaCl, 3 KCl, 1.2 MgSO 4 , 1.2 CaCl 2 , 1 NaH 2 PO 4 , 22 NaHCO 3 , and 10 glucose (aerated with 95% O 2 and 5% CO 2 ), pH 7.2-7.4. Synaptosomal protein contents were determined according to Bradford (1976 3 H]NE of serotonergic and dopaminergic nerve terminals, respectively. After the labeling period, identical portions of the synaptosomal suspensions were distributed on a set of parallel superfusion chambers maintained at 37°C . Superfusion was then performed at a flow rate of 0.5 ml/min, using media aerated with 95% O 2 and 5% CO 2 , for a total period of 51 min.
Synaptosomes were first equilibrated during 36 min of superfusion; five consecutive 3-min fractions (termed "b1 to b5") were then collected. Tat or its fragments were introduced at the end of the first fraction (b1; t ϭ 39 min), whereas glutamate receptor antagonists xestospongin C, dantrolene, oligomycin, or 8-bromo-cyclic adenosine diphosphateribose (Br-cADP-ribose) were present from 8 min before Tat or its fragments until the end of superfusion.
In a series of experiments, performed to study the Ca 2ϩ dependency of the Tat-induced release, the superfusion medium was replaced, starting from t ϭ 20 min, with a medium containing 0.1 mM Ca 2ϩ and in which the Mg 2ϩ concentration was increased to 10 mM to prevent the entry of Ca 2ϩ through voltage-sensitive Ca 2ϩ channels (VSCCs). Fractions collected and superfused synaptosomes were finally counted for radioactivity or analyzed for their endogenous amino acid content.
Endogenous amino acid determination. Endogenous amino acids were determined by HPLC analysis (Waters 715 Ultrawisp; Waters Associates, Milford, MA) after automatic derivatization with o-phthalaldehyde and resolution through a C18 reverse-phase chromatographic column (Chrompack, Middleburg, The Netherlands; 10 ϫ 4.6 mm, 3 m; 30°C), coupled with fluorimetric detection (Shimadzu, Tokyo, Japan; RF551; excitation wavelength, 350 nm; emission wavelength, 450 nm). The compounds were eluted with a Waters 600 MS gradient system after a ternary gradient program, as described previously (Pittaluga et al., 1997) . Homoserine was used as internal standard.
Endogenous cADP-ribose determination. Rat cortical synaptosomes (0.3 mg of protein/tube) were incubated for 8 min at 37°C in a rotary water bath in the absence (control) or in the presence of Tat (1 nM). At the end of the incubation period, HClO 4 (final concentration, 0.6 mM) was added to stop the enzymatic reactions, and samples were rapidly frozen until cADP-ribose determination. Synaptosomal c-ADP-ribose content was analyzed according to Graeff and Lee (2002) .
Denaturation or immunoprecipitation of Tat. Tat was denaturated by heating at 90°C for 30 min. Immunoprecipitation was performed by incubating the protein (100 nM) with a rabbit anti-Tat polyclonal antibody (1:500) in the presence of goat anti-rabbit IgG agarose for 90 min at room temperature. The suspension was then centrifuged, and the supernatant was immediately used in release experiments.
Calculations. The amounts of endogenous amino acids released into each superfusate fraction were expressed as picomoles per milligram of protein. The effects of Tat on the release of endogenous transmitters were evaluated by calculating the ratio between the amino acid content in the fraction in which the maximal effect was reached (usually b4, the fourth fraction collected) and the amount in the first fraction (b1) and comparing this ratio with the corresponding ratio obtained under control conditions (no drug added).
The amount of radioactivity released into each superfusate sample was expressed as a percentage of the total synaptosomal radioactivity content at the start of the fraction collected (fractional efflux). When the time course of the Tat effect is described, the amount of radioactivity into each superfusate fraction collected was expressed as the percentage of the first fraction collected (b1). When results are expressed as percentage of increase over basal release, drug effects were evaluated from the ratio between the percentage of release in b4 and that in b1. This ratio was compared with the corresponding ratio obtained under control conditions (no drug added). ANOVA was performed, followed by Dunnett's test or Newman-Keuls multiple comparisons test, as appropriate. 
Results

Tat selectively enhances [ 3 H]ACh release
We first investigated the effects of Tat on the release of different transmitters from human and rat cortical superfused synaptosomes. As shown in Table 1 , Tat, added to the superfusion medium at 1 or 3 nM, did not affect the release of endogenous aspartate, glutamate, GABA, or serine. The protein also had no effect on the release of previously taken up As shown in Figure 1 A, the Tat-induced [ 3 H]ACh release from human cortical synaptosomes reached a maximal effect at b3 (i.e., after 6 min of exposure to the protein); heat shock denaturation or immunoprecipitation of Tat prevented its releasing effect. The protein also elicited release of [ 3 H]ACh from rat cortical synaptosomes (Fig. 1 B) . Similarly, the releasing effect produced by 1 nM Tat was prevented by immunoprecipitation or heat shock denaturation. When tested at varying concentrations (0.1-3 nM), Tat appeared to reach a maximum effect at ϳ1 nM (Fig. 1C,D) . ions. Drastic reduction of Ca 2ϩ (to 0.1 mM) in the superfusion medium and the simultaneous increase of Mg 2ϩ ions to 10 mM prevented the Tat-induced release by ϳ55% (Fig. 2 A) . Moreover, 3 H]NE ϭ 1.67 Ϯ 0.16%. The release in b1 is expressed as picomoles per milligram of protein in the case of endogenous transmitters and as a percentage of the total synaptosomal tritium content at the onset of the collection period in the case of the radiolabeled transmitters. Synaptosomes were exposed to Tat from the end of b1 throughout superfusion. The effect of Tat is expressed as the percentage of increase over basal. Data are means Ϯ SEM of the number of experiments (in parentheses) run in triplicate (three superfusion chambers for each experimental condition). Cd 2ϩ ions (10 M) diminished to the same extent the releasing effect of the protein in human nerve endings. In contrast, the Tat-induced release was almost completely (ϳ85%) prevented when the membrane-impermeant Ca 2ϩ chelator BAPTA was entrapped in the synaptosomes, suggesting that Ca 2ϩ release from internal stores also contributes to the releasing effect of Tat from human nerve endings (Fig. 2 A) .
Involvement of IP 3 in the Tat-evoked release from human nerve endings
Tat has recently been proposed to mobilize Ca 2ϩ from the endoplasmic reticulum through activation of IP 3 -sensitive receptors (Haughey et al., 1999) . To verify the occurrence of such a process in our system, we incorporated the membrane-impermeant IP 3 receptor (IP 3 r) antagonist heparin (40 M in the homogenization medium; estimated internal concentration, ϳ200 nM) into human synaptosomes. As shown in Figure 2 A, heparin prevented ϳ75% of the Tat-induced [ 3 H]ACh release. At the concentration used, heparin was previously found to prevent the somatostatininduced NMDA receptor potentiation of NE release from rat hippocampal synaptosomes . The involvement of IP 3 -sensitive Ca 2ϩ stores is also indicated by the finding that xestospongin C, a recently available membrane-permeant IP 3 r antagonist (Gafni et al., 1997) , inhibited the Tat-induced release of [ 3 H]ACh from human synaptosomes (Fig. 2 A) . (Fig. 2 B) (Fig.  2 B) . Because intraterminal Ca 2ϩ may originate from sources other than IP 3 -sensitive stores (for review, see Berridge, 1998; Mattson et al., 2000) , we investigated the effect of dantrolene, an antagonist at ryanodine receptors (RYRs), and of oligomycin, an inhibitor of the mitochondrial ATPase. As shown in Figure 2 B, dantrolene dramatically reduced the Tat-evoked release from rat synaptosomes, whereas oligomycin had no effect. At the concentrations used, dantrolene and oligomycin were previously found to inhibit the external Ca 2ϩ -independent K ϩ -induced GABA release from rat cortical synaptosomes (Raiteri et al., 2002) as well as NGF-mediated potentiation of K ϩ -induced glutamate release (Raiteri et al., 2003) .
The Tat-evoked [ 3 H]ACh release from human and rat cortical nerve endings does not involve activation of glutamate ionotropic receptors
It had been proposed that Tat can directly excite human and rodent neurons via activation of non-NMDA receptors (Magnuson et al., 1995) . We found that human cortical nerve endings are endowed with AMPA/kainate receptors, activation of which causes [ 3 H]ACh release; this effect is prevented by NBQX, an AMPA/kainate-preferring antagonist (100 M AMPA ϭ 28.4 Ϯ 2.1%; 100 M AMPA ϩ 10 M NBQX ϭ 0.3 Ϯ 5.8%; p Ͻ 0.01; results were expressed as the percentage of increase over basal release). Release-mediating AMPA/kainate receptors also are present on rat cortical nerve endings (Pittaluga et al., 1997) .
We investigated whether the effect of Tat on [ 3 H]ACh release from human and rat cortical synaptosomes could depend, at least in part, on the activation of ionotropic glutamatergic receptors; however, the selective AMPA/kainate receptor antagonists NBQX (10 M) and LY303070 (10 M), as well as the competitive NMDA receptor antagonist CGS19755 (10 M), failed to significantly affect the Tat-induced release (Table 2) . At the concentrations indicated, the antagonists did not affect, on their own, the spontaneous release of tritium. Table 4 ; the releasing effect induced by 3,5-DHPG (100 M) was almost totally antagonized by MPEP (1 M) and CPCCOEt (5 M). Of note, 3,5-DHPG (100 M) did not cause the release of The Tat-evoked release from rat nerve endings involves cADP-ribose RYRs are thought to be endogenously activated by cADP-ribose (Galione et al., 1993; Fossier et al., 1999; Higashida et al., 2001; Lee, 2001) . Data are present in the literature demonstrating that in the cholinergic system of frog motor nerve terminals (Brailoiu and Miyamoto, 2000) and Aplysia buccal ganglion neurons (Mothet et al., 1998) , the injection of cADP-ribose facilitates ACh release in a Ca 2ϩ -dependent manner. To investigate whether the Tat effect in rat cerebrocortex synaptosomes is mediated by cADP-ribose, synaptosomes were exposed to Tat in the presence of Br-cADP-ribose, a membrane-permeant competitive antagonist of the cADP-ribose-binding site (Walseth and Lee, 1993) . As reported in Table 5 , Br-cADP-ribose prevented the Tat-induced release of [ 3 H]ACh. At the concentrations used, the compound did not affect, on its own, the release of [
3 H]ACh (data not shown). Exposure of rat synaptosomes to Tat (1 nM) caused a moderate, but significant, increase in the cADP-ribose content [control: 2.49 Ϯ 0.12 pmol/mg protein, n ϭ 8; with added Tat (1 nM): 3.18 Ϯ 0.24, n ϭ 10; p Ͻ 0.05]. This effect is probably underestimated, if one assumes that the cADP-ribose increase essentially occurs in cholinergic synaptosomes, representing only a small percentage of the cortical population of nerve endings. The cADP-ribose detected in the synaptosomal fraction is consistent with the cADP-ribose level reported in the CNS by Walseth et al. (1991) .
In contrast, the Tat-evoked release of [ 3 H]ACh from human cortical nerve endings was insensitive to Br-cADP-ribose (1 nM Tat ϭ 77.3 Ϯ 4.5; 1 nM Tat in the presence of 10 M Br-cADPribose ϭ 86.6 Ϯ 8.7; results are expressed as the percentage of increase over basal release).
Different peptide fragments mimic Tat in human versus rat nerve endings
To identify the peptide sequences responsible for the effects of Tat on the release of [ 3 H]ACh, different fragments of the protein were tested on human and rat cortical synaptosomes prelabeled with [
3 H]choline. Figure 3A shows that Tat 32-62 (1 nM) and Tat 49 -86 (1 nM) elicited [
3 H]ACh release from human synaptosomes. In contrast, rat synaptosomes only released [ 3 H]ACh when exposed to 1 nM Tat 49 -86, whereas the response to Tat 32-62 was very weak and barely significant (Fig. 3B) . Indeed, Tat 49 -86 (1 nM) increased [ 3 H]ACh release from rat beginning at 0.1 nM, whereas Tat 32-62 was unable to release [ 3 H]ACh, even when up to 10 nM were added (Fig. 3B, inset) .
Finally, rat cortical synaptosomes were exposed to different partially overlapping amino acid fragments collectively spanning the entire Tat sequence. All peptides were applied at the final concentration of 1 nM. As shown in Figure 4 , the [ 3 H]ACh release was significantly increased only by Tat 61-80, whereas the other peptides were ineffective. The effects of four consecutive 20mers spanning the entire Tat sequence were also evaluated on the release of [
3 H]ACh from human cortical synaptosomes. Figure 4 shows that only the sequence Tat 41-60 was able to evoke [ 3 H]ACh release, whereas the other sequences, including Tat 61-80, were much less effective or ineffective.
Discussion
Tat interacts with human and rodent brain neuronal membranes, leading to depolarization and increase in cytosolic [Ca 2ϩ ] (Sabatier et al., 1991; Cheng et al., 1998; Haughey et al., 1999 Haughey et al., , 2001 . In nerve endings, such events could activate transmitter release (Berridge, 1998) . To investigate this possibility, human and rat synaptosomes were exposed to Tat, and the release of various neurotransmitters was monitored.
The first finding of this work is that Tat can increase the basal release of ACh from both human and rat nerve endings. The characteristics of the technique used to monitor release (updown superfusion of thin layers of synaptosomes) permit the exclusion of indirect effects and lead to the conclusion that Tat acts by binding to sites located on cholinergic axon terminals.
Tat exhibits neuronal selectivity as determined by the proteinevoked release of ACh but was unable to elicit release of glutamate, aspartate, GABA, serine, and [ 3 H]NE. These results indicate that, among the neuronal families examined, only cholinergic neurons possess Tat recognition sites, the activation of which leads to transmitter release. Note that the concentrations of Tat (Ͻ1 nM) able to significantly enhance the release of ACh approach those proposed to be present extracellularly during HIV-1 infection (Gurwell et al., 2001) .
Buffering cytosolic Ca 2ϩ ions with the Ca 2ϩ chelator BAPTA almost completely prevented the releasing effect of Tat from both human and rat synaptosomes. Therefore, it is reasonable to assume that the release of ACh provoked by Tat occurs by vesicular exocytosis dependent on Ca 2ϩ reaching the cytosol when Tat binds to cholinergic terminals. One way to increase cytosolic [Ca 2ϩ ] is by entry of external Ca 2ϩ ions through activated VSCCs. In human nerve endings, the releasing effect of Tat was about halved in low Ca 2ϩ medium or after the addition of Cd 2ϩ ions, which are known to block VSCCs. These findings indicate that external Ca 2ϩ ions and VSCC activation contribute to the Tat-induced ACh release from human cerebrocortical nerve endings in a consistent manner. In contrast, neither the removal of external Ca 2ϩ nor the addition of Cd 2ϩ ions significantly decreased the release of ACh elicited by Tat from rat synaptosomes, indicating that this BAPTA-sensitive release depends exclusively on Ca 2ϩ mobilization from intraterminal stores. If intraterminal Ca 2ϩ is the only source used by Tat to evoke ACh release from rat synaptosomes, ϳ50% of the Tat-evoked release from human axon terminals depends on this source. Surprisingly, however, the mechanisms involved in the two internal Ca 2ϩ -dependent releases clearly differ between human and rat nerve endings.
It is well known that intraneuronal Ca 2ϩ can be mobilized from endoplasmic reticulum, through the activation of IP 3 -sensitive and RY-sensitive receptors, as well as from mitochondria (for review, see Berridge, 1998; Mattson et al., 2000) .
In human cholinergic nerve endings, Tat causes Ca 2ϩ mobilization from IP 3 -sensitive stores because heparin and xestospon- gin C, two IP 3 r antagonists, strongly prevented the Tat-induced release of ACh. Intracellular IP 3 production usually requires activation of membrane metabotropic receptors. We found that cholinergic human, but not rat, terminals are endowed with group I mGluRs, mediating the Tat-releasing effect, because antagonists at group I mGluRs potently prevented the Tat-evoked  release of [ 3 H]ACh. The finding is compatible with the idea that Tat binds to mGluRs located on human cortical cholinergic terminals and causes IP 3 -mediated Ca 2ϩ release from intraterminal stores with consequent exocytosis of ACh.
Unlike for human nerve endings, Ca 2ϩ mobilization from IP 3 -sensitive stores can be excluded when Tat releases ACh from rat terminals because IP 3 r antagonists were unable to significantly prevent the Tat effect. The release of ACh elicited by Tat from rat nerve terminals was instead almost abolished by dantrolene, a RYR antagonist, indicating that intraterminal Ca 2ϩ in rat cholinergic nerve terminals is essentially mobilized after activation of RYRs. As mentioned previously, the endogenous agonist at RYRs is likely to be cADP-ribose (Galione et al., 1993; Lee, 2001) . The involvement of this intracellular second messenger in the Tat effect on rat cholinergic terminals is supported by the findings that (1) Br-cADP-ribose almost totally prevented the Tat-mediated releasing effect, and (2) Tat increased cADP-ribose synthesis in rat cortical synaptosomes. Oligomycin, a mitochondrial ATPase blocker, had no effect on Tat-evoked ACh release, indicating that mitochondrial Ca 2ϩ contributes little, if any, to the effect of Tat.
It had been proposed that Tat 1-72 can induce intracellular Ca 2ϩ mobilization from IP 3 -sensitive stores in human fetal neurons and astrocytes (Haughey et al., 1999) , whereas contradictory results are present in the literature concerning the rodent brain (Kruman et al., 1998) . Recently, Haughey et al. (2001) reported that Tat did not affect the basal levels of intracellular calcium on its own but that it facilitated the glutamate-triggered calcium flux through an IP 3 -dependent mechanism.
Involvement of RYRs in Ca 2ϩ mobilization by Tat has so far not been reported. Haughey et al. (2001) demonstrated that the Tat facilitatory effect on the glutamate-mediated Ca 2ϩ mobilization in rat hippocampal neurons was RYR independent. The inhibition of the Tat-induced ACh release by dantrolene as well as by Br-cADP-ribose observed here indicates that activation of RYRs plays a significant role. However, it remains to be understood how Tat can stimulate cADP-ribose production and consequent Ca 2ϩ mobilization from RY-sensitive stores. Tat can act both intracellularly or extracellularly (Ensoli et al., 1993; Milani et al., 1998; Lindgren et al., 2000) , but an intracellular action of the protein seems unlikely in our system because entrapped heparin, a Tat scavenger (Rusnati et al., 1997) , failed to prevent the releasing effect. If Tat binds extracellularly, it might be recognized by as yet unidentified sites on rat cholinergic neurons, the activation of which leads to cADP-ribose production.
The Tat-releasing effect on human synaptosomes is retained by the peptide fragments 32-62, 49 -86, and 41-60, suggesting that Tat binds at human cortical cholinergic terminals through a sequence encompassing positions between 49 and 60. The three peptides contain the arginine-rich basic region (Tat 49 -57) that not only is critical for efficient trans-activation (Ensoli et al., 1993) , but is also required to induce depolarization in human fetal neurons (Nath et al., 1996) , making it a potential candidate for the effect on ACh release. At variance with this possibility, the effect of Tat on rat cortical nerve endings maps to another region, because Tat 49 -86, but not Tat 32-62, potentiated the release of ACh; this ability was retained by the peptide 61-80, but not by the flanking regions 51-70 and 71-80.
Conclusions
In conclusion, we found that the HIV-1 protein Tat can evoke release of ACh from human and rat cerebrocortex cholinergic axon terminals with remarkable neuronal selectivity. The mechanisms involved in the release from human terminals differ strikingly from those in rodent terminals. In human terminals, Tat behaves as an extremely potent agonist at IP 3 -linked mGluRs of group I, able to mobilize intraterminal Ca 2ϩ and consequently to elicit exocytotic-like ACh release. The binding of Tat to rat terminals leads to ACh release that is also dependent on intraterminal Ca 2ϩ but which is mobilized after RYR activation, possibly via their putative endogenous agonist cADP-ribose. If this is the case, Tat could be considered a potent activator of an as yet unidentified membrane receptor linked to the second messenger cADP-ribose. That Tat binds to different recognition sites on human versus rat cholinergic terminals is also indicated by the finding that the releasing effect of Tat in human terminals is mimicked by peptide fragments different from those mimicking it in rat terminals. Previously, we found that the HIV-1 coat protein gp120 potentiates the release of norepinephrine from human (Pittaluga et al., 1996) and rat (Pittaluga and Raiteri, 1994) cortical axon terminals. In contrast with Tat, gp120 acts, in both human and rat terminals, on glutamate NMDA receptors as a very potent agonist of the glycine site. The present data on Tat indicate that, although the protein elicits ACh release from both human and rat cholinergic terminals, the mechanisms are different and, therefore, the rodent model should be exploited with caution. Of note, the disease state of patients seems not to be involved in the species difference observed here, because data obtained from different patients did not differ significantly from each other. In contrast, species differences among presynaptic receptors mediating neurotransmitter release have been reported to occur in mammalian brains (Hoyer and Middlemiss, 1989) .
The pathophysiological significance of the Tat effect on ACh release observed here is presently unknown. The Tat concentrations used are likely to be lower than those causing overt neurotoxicity. However, it must be noted that, once present in the brain extracellular fluid, Tat may not be easily inactivated and may, therefore, provoke release of ACh outside of the physiological range and with abnormal kinetic characteristics, potentially contributing to the cognitive disturbances characteristic of AIDS dementia.
